Literature DB >> 15478146

Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis.

Chunhua Yang1, Jieruo Gu, Markus Rihl, Dominique Baeten, Feng Huang, Miansong Zhao, Hanwei Zhang, Walter P Maksymowych, Filip De Keyser, Eric M Veys, David T Y Yu.   

Abstract

OBJECTIVE: To assess the usefulness of measuring serum matrix metalloproteinase 3 (MMP-3) and macrophage colony-stimulating factor (M-CSF) in patients with ankylosing spondylitis (AS).
METHODS: Serum levels of MMP-3 and M-CSF were measured in AS patients who did and did not receive infliximab treatment. These were compared with those of 28 healthy subjects.
RESULTS: In the group of AS patients not treated with biologics, both M-CSF and MMP-3 correlated with the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) values, but not with each other. Logistic regression analysis showed that MMP-3 values were high in those with severely active disease. Infusions of infliximab in AS patients led to a significant decrease in the values of the BASDAI as well as the serum MMP-3, but no change in the serum M-CSF values.
CONCLUSION: MMP-3 and M-CSF are potentially useful markers of AS disease activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15478146     DOI: 10.1002/art.20696

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  29 in total

1.  Screening and evaluating the mimic peptides as a useful serum biomarker of ankylosing spondylitis using a phage display technique.

Authors:  Min Wang; Xianping Li; Jingwei Chen; Yong Zhou; Hong Cao; Xiang Wu; Hongmin Jiang
Journal:  Rheumatol Int       Date:  2010-03-19       Impact factor: 2.631

Review 2.  Novel therapies for ankylosing spondylitis.

Authors:  Walter P Maksymowych
Journal:  Curr Rheumatol Rep       Date:  2005-06       Impact factor: 4.592

Review 3.  Outcomes in ankylosing spondylitis: what makes the assessment of treatment effects in ankylosing spondylitis different?

Authors:  M M Ward
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

4.  Increased expression of macrophage colony-stimulating factor in ankylosing spondylitis and rheumatoid arthritis.

Authors:  P-T Yang; H Kasai; W-G Xiao; L-J Zhao; L-M He; A Yamashita; X-W Deng; M Ito
Journal:  Ann Rheum Dis       Date:  2006-12       Impact factor: 19.103

Review 5.  Biomarker development for axial spondyloarthritis.

Authors:  Matthew A Brown; Zhixiu Li; Kim-Anh Lê Cao
Journal:  Nat Rev Rheumatol       Date:  2020-06-30       Impact factor: 20.543

Review 6.  Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis.

Authors:  John D Reveille
Journal:  Clin Rheumatol       Date:  2015-05-05       Impact factor: 2.980

7.  Involvement of neurotrophins and their receptors in spondyloarthritis synovitis: relation to inflammation and response to treatment.

Authors:  M Rihl; E Kruithof; C Barthel; F De Keyser; E M Veys; H Zeidler; D T Y Yu; J G Kuipers; D Baeten
Journal:  Ann Rheum Dis       Date:  2005-04-07       Impact factor: 19.103

8.  M-CSF mediates TNF-induced inflammatory osteolysis.

Authors:  Hideki Kitaura; Ping Zhou; Hyun-Ju Kim; Deborah V Novack; F Patrick Ross; Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2005-11-17       Impact factor: 14.808

9.  Correlation of serum MMP3 and other biomarkers with clinical outcomes in patients with ankylosing spondylitis: a pilot study.

Authors:  Dongyi He; Qi Zhu; Quan Zhou; Qing Qi; Hongmei Sun; Liza M Zachariah; Grace Wang; John D Reveille; Yongtao Guan; Xiaodong Zhou
Journal:  Clin Rheumatol       Date:  2017-04-22       Impact factor: 2.980

10.  Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis.

Authors:  Consuelo Romero-Sánchez; William H Robinson; Beren H Tomooka; John Londoño; Rafael Valle-Oñate; Feng Huang; Xiaohu Deng; Liyun Zhang; Chunhua Yang; David Tak Yan Yu
Journal:  Clin Rheumatol       Date:  2008-06-20       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.